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BRIEF COMMUNICATION
Lowe syndrome, or the oculocerebrorenal syn-
drome of Lowe (OCRL) (OMIM #309000), was
first described by Lowe et al in 1952.1 It is an X-
linked multisystem disorder with the hallmark
features of ocular defects (congenital cataracts,
glaucoma, searching nystagmus, microphthalmos,
corneal keloids, and decreased visual acuity), cen-
tral nervous system defects (generalized hypoto-
nia with decreased or absent deep tendon reflex,
and profound mental retardation), and renal
dysfunction (hydronephrosis, Fanconi syndrome
with renal tubular acidosis and generalized
aminoaciduria, and progressive renal tubular dys-
function).1–3 Growth failure, cognitive problems,
maladaptive behaviors including tantrums and
stereotypes, and scoliosis are also cardinal fea-
tures.1–5 The common causes of death in these
patients include infection, status epilepticus, and
chronic renal failure, usually in or after the second
decade of life.2–4 OCRL is caused by mutations in
the OCRL1 gene. The genetic abnormality results
in an inborn error of inositol phosphate metabo-
lism with subsequent dysplasia in the eyes, brain,
kidneys, and fibroblasts in the bones and teeth.6
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Amelioration of Hypophosphatemic Rickets
and Osteoporosis With Pamidronate and
Growth Hormone in Lowe Syndrome
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The oculocerebrorenal syndrome of Lowe, an X-linked multisystem disorder, was diagnosed in a male pa-
tient who presented with typical abnormalities of the eyes, kidneys and nervous system. Besides congeni-
tal cataracts, renal tubular dysfunction and psychomotor retardation, the patient had also suffered from
profound failure to thrive, growth hormone deficiency, severe osteoporosis with hypophosphatemic rick-
ets, and progressive renal dysfunction since early childhood, which were attributed to the metabolic de-
rangements following Fanconi syndrome. Direct sequencing of the OCRL1 gene (responsible for the
oculocerebrorenal syndrome of Lowe) revealed a de novo c.2282_2283insT in exon 20, which resulted in
premature termination of translation (D762X). After monthly intravenous administration of pamidronate
since the age of 17.8 years, his urine creatinine clearance and tubular resorption of phosphate increased
slightly and bone mineral density was much improved (Z score increased from –7.3 to –3.3) without de-
terioration of renal function. Simultaneous growth hormone therapy enhanced the positive response. The
beneficial osseous and renal effects of the bisphosphonate, along with growth hormone treatment in Lowe
syndrome with hypophosphatemia, may be related to reduced renal calcium and phosphate excretion. 
[J Formos Med Assoc 2009;108(9):730–735]
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Skeletal involvement secondary to renal 
function impairment, Fanconi syndrome with
hypercalciuria and hyperphosphaturia in OCRL
is often encountered.2–5 Until now, only support-
ive therapy with calcium and sodium bicarbonate
supplementation has been possible. Bisphospho-
nates have been useful in treating conditions that
promote excessive bone resorption and hypercal-
cemia, such as Paget’s disease, osteoporosis and
various malignancies.7 Recently, the clinical indi-
cations for intravenous bisphosphonates have
continued to expand.7–9 In this report, a male pa-
tient with a de novo mutation of OCRL1 received
intravenous bisphosphonate (pamidronate dis-
odium), along with recombinant human growth
hormone (GH) therapy for severe osteoporosis
and GH deficiency. The potential use of pami-
dronate and/or GH to treat hypophosphatemic
rickets as a new aspect of OCRL treatment is
highlighted, and renal safety is discussed.
Case Report
A Taiwanese boy with OCRL was followed-up
since early infancy. He was the fourth child born
to young healthy parents, with a birth weight of
3.13 kg. All three of his elder sisters have normal
growth and health. Congenital cataracts and 
hypotonia were noted after birth. He underwent 
bilateral lens removal at the age of 2 months,
when the diagnosis of Fanconi syndrome was
made because of the presence of bicarbonaturia,
renal tubular acidosis, generalized aminoac-
iduria, hyperphosphaturia, and impaired urine-
concentrating ability. Marked postnatal growth
retardation developed and all growth parameters
were below the third percentile after 1.5 years.
The patient exhibited a facial appearance with
frontal bossing, chubby cheeks, and a fair com-
plexion. He suffered from frequent respiratory in-
fections complicated with sepsis, conjunctivitis,
enteritis, recurrent pneumonia that led to chronic
lung disease, and urinary tract infections with vesi-
coureteral reflux (from grade II at 9 years to grade
V after 16 years). Tracheostomy was performed
at 10 years of age for tracheal polypoid granulo-
matosis after ineffective broncholaser treatment.
At the age of 17.5 years, he was extremely
short (83.0 cm in height, and 12.0 kg in weight)
and had microcephaly (head circumference of
45 cm). Dysmorphic features included sparse/
hypopigmented hair, frontal bossing, enophthal-
mos with blue sclerae, cloudy cornea, esotropia,
queer eye movements or pendular nystagmus,
ear dysplasia, dental dysplasia with oligodontia,
full cheeks (Figure 1), barrel chest, rocker bottom
feet, but no plantar masses. The skin showed a
lack of subcutaneous fat, and frequent occur-
rence of purpura, ecchymosis and dermatitis. 
His blood pressure was 110/70 mmHg. Unusual
repetitive limb movements and irritability or
rigidity were noted, but there was no digit or
joint swelling. Bone fractures interfered with the
rehabilitation program.
Laboratory findings were as follows: hemoglo-
bin, 8.5 g/dL; platelet count, 120 × 109/L; meta-
bolic acidosis (pH 7.167; base excess, –19.8);
and impaired renal function (Table). His thyroid
function, liver enzymes, plasma total/free carni-
tine levels, and serum bilirubin, sodium and
potassium were within normal ranges. Secondary
hyperparathyroidism was noted, with 8.54 μg/L
(7.7–53.5 μg/L) 25-hydroxy-vitamin D and
49.2 nmol/L (60–108 nmol/L) calcitriol. Urinalysis
revealed proteinuria (25 mg/dL), glucosuria (0.3 g/
dL), reduced creatinine, and elevated calcium
and phosphate excretion (Table).
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Figure 1. The patient at 17.5 years of age.
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Roentgenographic studies showed diffuse os-
teoporosis with old fractures in many ribs, kyp-
hoscoliosis of the thoracolumbar spine, deformity
of the thoracic cage, flattening of the lumbar ver-
tebral bodies (Figure 2), and bilateral angulation
of the femoral proximal shaft and neck. Bone
scintigraphy showed increased radioisotope up-
take over the peripheral bones but an absence of
radioactivity over the epiphyseal growth plates of
the major joints. Renal ultrasonography revealed
increased echogenicity with a small right kidney,
moderate right and severe left hydronephrosis
with thin renal cortices, dilated calyx, dilated tor-
tuous left ureter, and a huge bladder with trabec-
ulation. Neurogenic bladder and grade II (right)
and V (left) vesicoureteral reflux were found after a
voiding cystourethrography examination.
Brain magnetic resonance imaging studies
showed brain atrophy with ventriculomegaly, and
multiple cysts or lacunar infarcts over bilateral
periventricular white matter and centrum semio-
vale, which indicated a demyelinating process.
Magnetic resonance urography showed obstruc-
tive nephropathy with bilateral hydronephrosis
and hydroureter (Figure 3). The level of insulin-
like growth factor I (IGF-I) was rather low
(11.3 nmol/L; range, 38.1–82.3 nmol/L). His skele-
tal age was only 6 years. Measurement of bone
mineral density (BMD) of the lumbar spine
(L1–L4) by dual-energy X-ray absorptiometry
showed severe osteoporosis (Table). Gradual loss
of renal function with elevated creatinine and
blood urea nitrogen was seen, with reduction 
of creatinine clearance (CCr) from 21.5 to
Table. Clinical and laboratory findings before and after pamidronate treatment
Course (mo) –12 –6 0 6 12 18 24 32 38
Treatment
Pamidronate
Recombinant human GH
Body height (cm) 82.8 83.0 83.0 85.0 89.0 92.0 96.0 99.5 101.1
Body weight (kg) 11.0 12.3 12.0 12.0 12.1 13.0 14.5 15.1 16.0
iPTH (pmol/L) NA NA 25.3 36.5 39.0 28.2 15.2 17.3 20.1
AP (U/L) NA 284 290 185 177 154 160 151 150
Osteocalcin (ng/mL) NA NA 66.0 51.5 41.0 29.8 31.2 28.7 27.4
PINP (ng/mL) NA NA 286 212 104 99.5 70.2 46.5 40.6
ICTP (ng/mL) NA NA 52 34.2 29.8 21.3 11.6 10.1 9.9
BMD (g/cm2) NA NA 0.284 0.342 0.425 0.432 0.570 0.612 0.640
Z score (SD) NA NA –7.3 –6.8 –5.3 –5.2 –4.1 –3.5 –3.3
Ca (mg/dL) 6.5 NA 6.3 7.7 8.6 8.8 8.8 8.9 9.0
P (mg/dL) 4.1 NA 4.8 4.1 4.4 4.1 4.5 4.5 4.7
BUN (mg/dL) 55 46 58 39 31 30 30 23 23
Cr (μmol/L) 2.4 2.6 2.5 2.1 1.2 1.1 1.0 0.8 0.9
Urine Cr (mg/dL) NA NA < 4.0 5.0 7.8 10.0 11.0 13.0 13.1
Urine Ca/Cr NA NA 1.20 1.00 0.51 0.22 0.15 0.1 0.08
Urine P/Cr NA NA 1.03 0.80 0.56 0.12 0.09 0.08 0.08
TRP (%) NA NA 25 29 NA 35 41 49 54
CCr (mL/min/1.73 m2) 21.5 NA 17.5 19.1 23.2 24.8 25.5 29.3 30.3
IGF-I (nmol/L) NA NA 11.3 NA NA 12.5 21.2 34.6 33.1
Normal values in parentheses. iPTH = intact parathyroid hormone (0.95–6.8 pmol/L); NA = not available; AP = alkaline phosphatase
(68–260 U/L); osteocalcin (10.7–39.4 ng/mL); PINP = procollagen I N-telopeptide (20–76 ng/mL); ICTP = collagen I telopeptide
(1.3–5.2 ng/mL); BMD = bone mineral density; Z score = standard deviation for age-matched males; Ca = calcium (8.4–9.9 mg/dL);
P = phosphate (2.5–5.1 mg/dL); BUN = blood urea nitrogen (6–21 mg/dL); Cr = blood creatinine (27–62 μmol/L); Urine Ca/Cr = urine
Ca:creatinine ratio (< 0.2); Urine P/Cr = urine phosphate:creatinine ratio (< 0.2); TRP = tubular resorption of phosphate (> 80%);
CCr = creatinine clearance (97–137 mL/min/1.73 m2); IGF-I = insulin-like growth factor I (38.1–82.3 nmol/L).
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17.5 mL/min/1.73 m2, and 25% tubular resorp-
tion of phosphate (Table).
His mother has normal renal and liver func-
tion, urinalysis and blood pressure. Neither mi-
cropunctate nor posterior cortical cataracts could
be detected by slit-lamp examination in his
mother and three elder sisters. The karyotype of
the patient was 46,XY, whereas that of his mother
and three sisters was 46,XX. A mutation—insertion
of a T base between nucleotides 2282 and 2283 in
exon 20 (c.2282_2283insT)—in the OCRL1 gene
was identified. This led to a frameshift DNA mu-
tation that resulted in a stop codon mutation
(AspTGA) that results in premature termina-
tion of translation (D762X) after direct sequencing
of the total OCRL1 gene (24 exons) (Figure 4). No
female carriers could be detected in the patient’s
family.
At the age of 17.5 years, the patient began in-
travenous pamidronate disodium at a dose of
15 mg/m2 for 4 hours every month during the
next 3 years. Hemogram, urinalysis, and liver/renal
function tests were obtained every 2 months. Clin-
ical and laboratory findings before and after pami-
dronate treatment are shown in the Table. The
BMD Z scores increased significantly relative to
the baseline, from –7.3 to –3.3 after 3 years treat-
ment, particularly after simultaneous recombinant
human GH replacement therapy (0.023 mg/kg/
day, as for GH-deficient patients), via subcuta-
neous injection from months 18 to 34 (Table). No
further leg fracture occurred after the first course 
Figure 2. X-rays of the: (A) chest and (B) spine show dif-
fuse osteoporotic changes.
Figure 3. Magnetic resonance urography shows bilateral
small functioning kidneys with bilateral hydronephrosis
and more severe hydroureter of the left side, and relatively
earlier excretion of contrast medium from the renal pelvis
to right ureter.
A B C CA A AG GC T T T T T T TTCA AG G G GC
81 91
C CA A AG GC T T T T T T TTCA AG G G GC
81 91
A
B
Figure 4. DNA studies of the OCRL1 gene in (A) the 
patient and (B) his mother show a de novo T insertion 
between nucleotides 2282 and 2284 in exon 20, which 
resulted in a stop codon mutation (TGA) that leads to 
premature termination of translation (D762X).
of treatment. Pamidronate was well-tolerated and
there were no drug-related adverse events. Daily
urinary calcium and phosphate excretion and cal-
cium/creatinine ratio were reduced (Table) and
calcitriol level was normalized. Bone metabolism
markers and the level of intact parathyroid hor-
mone reduced gradually (Table). The patient was
also treated conservatively with calcium tablets,
sodium bicarbonate, folic acid, vitamin B complex
and vitamin C, and oral vitamin D3 at the same
time. The hemogram showed improvement of
hemoglobin level (12.2 g/dL) and platelet count
(202 × 109/L). He was noted to have more hair
growth and pigmentation, and improved activity,
mood and social interaction after these treatments.
Often, head turning or shaking persisted even
after hypocalcemia had been corrected. He can-
not talk but can only make sounds. He has five
residual primary teeth (mobile), and can sit alone
but cannot stand. He continued on therapy for
> 3 years without advanced renal impairment.
Furthermore, CCr was improved from 17.50 to
about 30 mL/min/1.73 m2 and tubular resorption
of phosphate from 25% to 54% (Table).
Discussion
Our patient showed several unusual features, in-
cluding severe growth retardation, missing teeth
with prolonged retention of residual primary
teeth, chronic lung disease, recurrent purpuric
macules, GH deficiency, and profound osteo-
porosis. Markedly retarded skeletal age associated
with absence of radioactivity over the epiphyseal
growth plates by bone scintigraphy, and low IGF-I
level indicated early cessation of skeletal devel-
opment. Repetitive limb movements and irritabil-
ity or rigidity, which may have been related to the
cerebral pathology, were noted even after recovery
of hypocalcemia. The improved hemogram is con-
sidered to be the result of better appetite and hence
intake of food and hematopoiesis after these treat-
ments. The musculoskeletal abnormalities may
have developed as secondary consequences of hy-
potonia, renal tubular acidosis, and generalized
aminoaciduria, hypocalcemia and hypercalci-
uria/hyperphosphaturia. Chronic metabolic aci-
dosis with a reduced renal acid excretory reserve
may increase alkali mobilization from the bone
and thus promote the development of osteo-
porosis, joint hypermobility and scoliosis.3,5,10
The initial highly elevated collagen I telopeptide
and procollagen I N-telopeptide levels were in-
dicative of severe bone resorption.
OCRL is inherited in an X-linked fashion and
the reported mutations consist of truncating 
mutations (frameshift, nonsense and splice site
mutations, and large genomic deletions), in-
frame deletion, and missense mutations.11 New
mutation occurs in about one third to a half of
patients,3,11,12 therefore, somatic or germinal mo-
saicism must be taken into account for genetic
counseling in this disease.11 Opacity and other
alterations of the cornea are a major problem in
the course of the disease.1–4,11 About 94% of fe-
male carriers can be detected using slit-lamp ex-
amination for the characteristic lenticular opacity,
and all genetically proven non-carriers lack this
phenotype.11 Thus, ophthalmological evaluation
may be a reliable first-line method to ascertain
the carrier state in OCRL, which can then be con-
firmed by molecular examination for genetic
counseling.11
The present case provides insight into the ef-
fects of pamidronate and GH on bone and kidney,
which may prevent or delay skeletal-related events
and provide benefits in renal tubular function in
OCRL. Intravenous bisphosphonates, which are
excreted intact primarily via the kidney, have im-
proved osteoporosis in various pediatric dis-
eases.9,13 However, risks of renal adverse reactions
after such therapy do exist and may aggravate the
preexisting impaired renal function, such as col-
lapsing glomerulopathy or tubulointerstitial in-
flammatory nephritis.7,14,15 Therefore, it has been
suggested that pamidronate infusion is contraindi-
cated in patients with severe renal impairment
(CCr < 30 mL/minute), unless in cases of life-
threatening tumor-induced hypercalcemia when
the benefit outweighs the potential risk, and
such treatment should be withheld until renal
J.W. Hou
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function returns to within 10% of the baseline
value or serum creatinine is < 1.2 mg/dL.7,8,14,15
However, from the present case report, monthly
infusions of 15 mg/m2 pamidronate for > 3 years
appear to be safe without aggravating renal insuf-
ficiency (Table). Furthermore, certain beneficial
long-term effects, including amelioration of hy-
pophosphatemic rickets following Fanconi syn-
drome, have been noted, as shown by renal
function in kidney transplant patients receiving
pamidronate for transplantation-associated bone
loss.13 The better outcome of these patients may
have resulted from an absence of predisposing
malignancies and the inhibitory effect of pami-
dronate, which is characterized by a decrease in
serum calcium and phosphate and a subsequent
decrease in their urinary excretion. Glomerular
filtration rate can be improved by controlling hy-
perphosphaturia/hypercalciuria, which can lead
to a reduced volume of extracellular fluid.14,15
Furthermore, when recombinant human GH was
administered together with pamidronate in our
patient, more significant improvement of bone
turnover parameters and BMD was noted (Table).
Close correlation between increased serum IGF-I
levels after GH treatment and increased phos-
phate reabsorption has been reported,16,17 which
further explains the mechanism of improved tu-
bular resorption of phosphate/glomerular filtra-
tion rate in our patient.
In conclusion, this case report shows that the
cyclical administration of intravenous pamidronate
has a positive impact on hypophosphatemia and
BMD in children with OCRL, particularly with early
adjunctive recombinant human GH replacement
therapy.
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